<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101722</url>
  </required_header>
  <id_info>
    <org_study_id>huadong FudanU</org_study_id>
    <nct_id>NCT03101722</nct_id>
  </id_info>
  <brief_title>Effects of Hearing Rehabilitative Interventions and Huperzine A on Presbycusis(Δ,kHz, dB,MMSE, AD)</brief_title>
  <official_title>Combination of Hearing Rehabilitative Interventions and Huperzine A for Presbycusis Related Tinnitus Suppression, Hearing and Cognitive Function Protection in Presbycusis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhijun Bao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effects of hearing aid, huperzine A and combination of hearing aid and
      huperzine A on tinnitus suppression, hearing and cognitive function protection in patients
      with presbycusis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To continuously recruit about 150 patients with presbycusis and tinnitus and about 400
      patients with presbycusis in our hospital of Fudan university.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The studies were divided into 4 groups: hearing aid, huperzine A, combination of hearing aid and huperzine A intervention and control group.The study is a single-center, double-blind, randomized, placebo controlled trial, with minimized allocation of patients to one of the four groups.
For the study of tinnitus intervention, there is a three to six month follow-up. For the study of hearing and cognitive function protection, there is a three year follow-up.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hearing function protection</measure>
    <time_frame>1-3 years</time_frame>
    <description>All participants (including with tinnitus and without tinnitus) will report in the measure.
Δ value of averaged hearing threshold = re-test threshold - initial threshold, Δ value of averaged hearing threshold ≤ 0 showed good responders, and &gt; 0 showed poor responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>global cognitive function protection</measure>
    <time_frame>3 years</time_frame>
    <description>All participants (including with tinnitus and without tinnitus) will report in the outcome measure.
ΔMMSE = re-test MMSE - initial MMSE, ΔMMSE&lt; 0 showed poor responders and hearing threshold ≤ 0 showed good responders; and &gt; 0 showed poor responders ΔMMSE≥ 0 showed good responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>special cognitive domains:orientation to time, orientation to place, registration, attention and calculations,recall, language,repetition and complex commands</measure>
    <time_frame>3 years</time_frame>
    <description>MMSE scale in different domains (MMSE SCALE, 0-30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tinnitus suppression</measure>
    <time_frame>3-6 months</time_frame>
    <description>150 participants with tinnitus will report in the outcome measure. Method 1: tinnitus functional index (0~100，≤25，relatively mild tinnitus; 25~50,significant problems with tinnitus; ≥50, tinnitus severe enough ）. method 2:no effect on tinnitus was showed &quot;0&quot;; symptomatic alleviation was showed &quot;1&quot;;and tinnitus disappear was showed &quot;2&quot;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Observation of liver and renal function</measure>
    <time_frame>1-3years</time_frame>
    <description>All participants (including with tinnitus and without tinnitus) will be observed.
The levels of serum alanine aminotransferase (ALT) u/L, aspartate aminotransferase (AST) u/L, alkaline phosphatase(ALP)u/L, total bilirubin (TBIL) μmol/L and direct bilirubin (DBIL) μmol/L were each measured by immunoenzymatic assays; Plasma creatinine (mg/L), Uric acid (mg/dl) and Glomerular filtration rate (ml/min/1.73m2).</description>
  </other_outcome>
  <other_outcome>
    <measure>adverse events related to treatment of Huperzine A</measure>
    <time_frame>1-3years</time_frame>
    <description>All participants (including with tinnitus and without tinnitus) will be observed gastrointestinal side effects (nausea, vomiting diarrhea)in yes or no, dizziness, fatigue and insomnia in yes or no</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Presbycusis</condition>
  <condition>Tinnitus</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>digital hearing aids intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digital hearing aid intervention to patients with best results</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Huperzine A intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Huperzine A intervention: Huperzine A with a dose 0.1~0.2 mg/time, 2 times/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>digital hearing aids and huperzine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Both digital hearing aids and huperzine A 0.1~0.2 mg/time, 2times/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>digital hearing aids,</intervention_name>
    <description>hearing aids intervention
experimental arm: both hearing aid and huperzine A Placebo Comparator:control</description>
    <arm_group_label>digital hearing aids intervention</arm_group_label>
    <arm_group_label>Huperzine A intervention</arm_group_label>
    <arm_group_label>digital hearing aids and huperzine A</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huperzine A</intervention_name>
    <description>huperzine A intervention</description>
    <arm_group_label>digital hearing aids intervention</arm_group_label>
    <arm_group_label>Huperzine A intervention</arm_group_label>
    <arm_group_label>digital hearing aids and huperzine A</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>acetylcholinesterase inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>digital hearing aids and Huperzine A</intervention_name>
    <description>both digital hearing aids and Huperzine A intervention</description>
    <arm_group_label>digital hearing aids intervention</arm_group_label>
    <arm_group_label>Huperzine A intervention</arm_group_label>
    <arm_group_label>digital hearing aids and huperzine A</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo Comparator</description>
    <arm_group_label>digital hearing aids intervention</arm_group_label>
    <arm_group_label>Huperzine A intervention</arm_group_label>
    <arm_group_label>digital hearing aids and huperzine A</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. mild to moderate/severe hearing impairment (the pure tone averaged across octave
             frequencies between 0.25 to 4 kHz of 26-79 dB HL) with or without tinnitus;

          2. tinnitus existing 3+ months;

          3. Han Chinese patients;

          4. aged above 60 years.

        Exclusion Criteria:

          1. air bone gap average across 0.5, 1 and 2 kHz ≤ 15 dB HL in better hearing ear;

          2. first language other than chinese;

          3. dependence due to poor physical activity;

          4. acute brain trauma and stroke within 2 weeks;

          5. psychiatric disorder;

          6. vision impairment;

          7. normal hearing or hearing impairment above 80 dB HL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhuowei yu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Institute of Geriatrics and Gerontology, Shanghai Key Laboratory of Clinical Geriatrics, Huadong Hospital, and Research Center of Aging and Medicine, Shanghai Medical College, Fudan University, Shanghai 200040, China.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>qingwei ruan, MD &amp; PhD</last_name>
    <phone>+86 13661717346</phone>
    <email>13661717346@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ruan</last_name>
    <email>qingweir@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huadong Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qingwei ruan</last_name>
      <phone>+86 13661717346</phone>
      <email>13661717346@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinshan Zhong Ren geriatric care hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>feng yao</last_name>
      <phone>+86 13611720583</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiuting Community Health Service</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yan zhang</last_name>
      <phone>+86 13661717346</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>July 30, 2017</last_update_submitted>
  <last_update_submitted_qc>July 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhijun Bao</investigator_full_name>
    <investigator_title>Huadong hospital, Fudan University, Clinical professor of Otolaryngology</investigator_title>
  </responsible_party>
  <keyword>presbycusis</keyword>
  <keyword>tinnitus</keyword>
  <keyword>cognitive impairment</keyword>
  <keyword>Huperzine A</keyword>
  <keyword>hearing aid</keyword>
  <keyword>age-related hearing impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Tinnitus</mesh_term>
    <mesh_term>Presbycusis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huperzine A</mesh_term>
    <mesh_term>Cholinesterase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

